NKTR   $0.454  -8.46% Market Closed

Nektar Therapeutics
Last Events:

2023-08-09 Signal in Stochastic changed from bearish weakening to bullish. The stochastic indicator is in the upper part of the neutral territory and it grows. These factors indicate that positive dynamics persists. Last signal: up-crossing the middle level.

2023-08-09 Signal in MACD changed from bearish weakening to bullish. Oscillator MACD is in the positive territory it's higher than the signal line and it crossed the zero line from the bottom. These factors mean that there is probably a growing trend. Last signal: up-crossing the middle level.

2023-08-09 Signal in RSI changed from bearish weakening to bullish. RSI indicator is in overbought territory and it grows. These factors indicate that the upside potential still holds even though the market is overbought. Last signal: entrance to the overbought zone.

2023-08-09 Signal in EMA100 changed from bearish reversal to bullish reversal. The price is trying to cross up the moving average line If the intersection will be successful, then an upside trend can be formed.

2023-08-09 Signal in EMA50 changed from bearish reversal to bullish reversal. The price is trying to cross up the moving average line If the intersection will be successful, then an upside trend can be formed.

2023-08-09 Signal in EMA20 changed from bearish reversal to bullish reversal. The price is trying to cross up the moving average line If the intersection will be successful, then an upside trend can be formed.

2023-08-06 Trend pattern changed from расходящийся клин с наклоном вниз to нисходящий клин.

2023-08-06 Signal in Stochastic changed from bearish to bearish weakening. The stochastic indicator is in the lower part of the neutral territory and it heading north. These factors indicate that the upside trend is forming Last signal: main and signal line crossing.


Current temperature: 2.70
ST: 0, Cor:

50-50 Year Forecast
Low with % probability:
Target: 0.51
High with % probability:
Analyst Recommendations:
Number of estimates 3
Target Price Mean 2.83
Mean unverified/preliminary 2.83 / 2.83
Target Price Low / High 0.50 / 5.00
Median / STD DEV 3.00 / 2.25
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total Sell Sell Sell
rsi Sell Sell None
macd Sell None None
stoch Sell None None
ma20 Sell Sell Sell
ma50 None None None
ma100 Sell Sell None
Candlestick PatternMarch 13, 2023 Doji - is formed when the open and the close are the same or very close. The body of candle is small. The length of the shadows are not important. The appearance of a Doji should alert the investor of major indecision.
ISIN US6402681083
ceo Mr. Howard W. Robin
Website https://www.nektar.com
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer squamous cell carcinoma and colorectal cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.